XML 197 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1
Debt - Liability for Sale of Future Royalties Narrative (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 18, 2023
USD ($)
Option
Jul. 17, 2020
USD ($)
Jun. 30, 2024
USD ($)
tranche
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Assigned royalty payments          
Cash consideration received from A&R Royalty Purchase Agreement       $ 241,792 $ 1,000,000
Assigned royalty payment, retained percentage   57.067%      
Remaining potential milestones that can be achieved       $ 150,000  
Effective interest rate of the liability component       9.80%  
Loss on extinguishment of debt         $ 137,558
Aggregate Royalty Purchase Agreements | Royalty Pharma          
Assigned royalty payments          
Aggregate percentage of royalty rights sold 80.9777%        
Original Royalty Purchase Agreement          
Assigned royalty payments          
Assigned royalty payment, percentage   42.933%      
Cash consideration received from A&R Royalty Purchase Agreement   $ 650,000      
Royalty purchase agreement termination period once there are no further royalty payment obligations   60 days      
Assigned Royalty Cap per terms of the royalty purchase agreement $ 1,300,000 $ 1,300,000      
Original Royalty Purchase Agreement | Royalty Pharma          
Assigned royalty payments          
Assigned Royalty Cap per terms of the royalty purchase agreement 1,300,000        
A&R Royalty Purchase Agreement          
Assigned royalty payments          
Cash consideration received from A&R Royalty Purchase Agreement $ 1,000,000   $ 241,800    
Assigned royalty payment, retained percentage     9.51%    
Royalty purchase agreement termination period once there are no further royalty payment obligations 60 days   60 days    
Effective interest rate of the liability component 10.80%   9.90%    
Retained Royalty Rights percentage sold 38.0447%        
Percentage of total royalty payable after threshold royalties received 66.6667%        
Additional cash consideration $ 500,000        
Aggregate percentage of royalty rights sold       90.49%  
Number of put options held by the company | Option 5        
Maximum number of put options which can be exercised before Royalty Pharma can exercise a call option | Option 2        
Maximum percentage of remaining retained royalty rights that are available upon exercise of call option 50.00%        
Percentage of maximum royalty payable until assigned royalty rights       83.33%  
Liability recognized for sale of future royalties.     $ 241,800    
Fair value of liability for sale of future royalties. $ 1,809,900        
Loss on extinguishment of debt $ 44,900        
Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met     16.67%    
A&R Royalty Purchase Agreement | Maximum          
Assigned royalty payments          
Number of tranches to sell retained royalty | tranche     3    
A&R Royalty Purchase Agreement | Royalty Pharma          
Assigned royalty payments          
Percentage of maximum royalty payable until assigned royalty rights 90.4888%        
Percentage of maximum royalty payable thereafter assigned royalty rights 83.3333%        
A&R Royalty Purchase Agreement | Royalty Pharma          
Assigned royalty payments          
Assigned Royalty Cap per terms of the royalty purchase agreement     $ 1,300,000    
Aggregate upfront cash consideration received for sale of future royalties       $ 1,900,000  
A&R Royalty Purchase Agreement Tranche One          
Assigned royalty payments          
Aggregate percentage of royalty rights sold     3.81%    
Contract price for sale of specified percentage of future royalties     $ 100,000    
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met     6.67%    
A&R Royalty Purchase Agreement Tranche Two          
Assigned royalty payments          
Aggregate percentage of royalty rights sold     3.81%    
Contract price for sale of specified percentage of future royalties     $ 100,000    
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met     6.67%    
A&R Royalty Purchase Agreement Tranche Three          
Assigned royalty payments          
Aggregate percentage of royalty rights sold     1.90%    
Contract price for sale of specified percentage of future royalties     $ 50,000    
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met     3.33%